HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales
Advancing toward heart attack detection as a key expansion of the platform
Tailoring its technology to fit each market, while operating with a leaner, more focused structure
Company to provide more details on strategy as part of Second Quarter 2026 conference call in August
